StemoniX CEO Ping Yeh Speaks at the 2020 New Jersey Association for Biomedical Research 3Rs Webinar Series
October 20, 2020 – In his talk, “Making Human Organs and the Path to Replacement,” Mr. Yeh discusses how the Company’s physiologically-relevant microOrgan® technology and human-first paradigm are de-risking drug discovery and preclinical drug development by compressing the pipeline and ensuring only the safest and most effective compounds are advanced to the clinic.
September 30 - October 1, 2020 – StemoniX Director of R&D, Dr. Cassiano Carromeu, did a fabulous presention on "Drug Discovery in 3D: Disease Modeling, Hit Stratification, and Clinical Translation with Human iPSC-derived 3D Neurospheroids" on Day 1. Dr. Blake Anson presented our poster, "Finding the Needle in the Haystack," on Day 2.
StemoniX participates in SBI2 High Content Meeting
September 16 - 17, 2020 – StemoniX exhibited and presented at the 7th Annual SBI2 High Content Meeting. Contact us to learn more about our poster: hiPSC-derived neurospheroids support assessment of glioblastoma cancer stem cell behavior and compound responses
September 7, 2020 – The StemoniX microBrain 3D platform was featured in a recent BioTechniques article! Read how our partners at Molecular Devices have used the microBrain 3D high-throughput, hiPSC-derived platform to study neurological dysfunction
StemoniX participates in the LabRoots Coronavirus 2020 Virtual Poster Session
July, 2020 – StemoniX presented a poster titled Using hiPSC-derived neural cultures to assess the safety of potential anti-viral therapeutics outlining how our high-content, consistent human cultures can be used to determine the safety and efficacy of anti-viral therapeutics
StemoniX ® CEO, Ping Yeh, Participates in an Organ- on-a-Chip and AI Focused Panel at the BIO2020 Digital Convention
June 9, 2020 – StemoniX ® , Inc., a biotech company revolutionizing how new medicines are discovered, announced today that its CEO and Co-founder, Ping Yeh, has joined a panel of experts from the FDA, the NIH, Pharma, and AI at this year’s BIO2020 Digital conference.